Browsing by Author "Matbouly S."

Now showing 1 - 4 of 4

Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia
(Wiley-Liss Inc., 2019) El-Khazragy N.; Elshimy A.A.; Hassan S.S.; Matbouly S.; Safwat G.; Zannoun M.; Riad R.A.; Department of Clinical Pathology and Hematology; Faculty of Medicine; Ain Shams Medical Research Institute (MASRI); Ain Shams University; Cairo; Egypt; Former Department of Biomedical Research; Armed Forces College of Medicine (AFCM); Cairo; Egypt; Department of Medical Microbiology and Immunology; Faculty of Medicine; Cairo University; New Giza University; Cairo; Egypt; Department of Clinical Pathology; National Cancer Institute; Cairo University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Department of Cancer Biology; Faculty of Biotechnology; October University for Modern Sciences and Art (MSA) University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Al Azhar University; Cairo; Egypt; Department of Biotechnology and Molecular Biology; Global Research Lab; Cairo; Egypt
Background: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.
In vitro knock-out of miR-155 suppresses leukemic and HCV virus loads in pediatric HCV-4 associated acute lymphoid leukemia: A promising target therapy
(Wiley-Liss Inc., 2019) Hassan S.S.; El-Khazragy N.; Elshimy A.A.; Aboelhussein M.M.; Saleh S.A.; Fadel S.; Atia H.A.; Matbouly S.; Tamer N.; Clinical Pathology Department; National Cancer Institute; Cairo University; Cairo; Egypt; Clinical Pathology/Hematology and Biomedical Research Departments; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Biomedical Research Department; Global Research Labs; Cairo; Egypt; Medical Microbiology and Immunology Department; Faculty of Medicine; Cairo University and New Giza University; Cairo; Egypt; Medical Biochemistry and Molecular Biology Department; Faculty of Medicine; Ain- Shams University; Cairo; Egypt; Internal Medicine Department; Faculty of Medicine; Ain- Shams University; Cairo; Egypt; Pediatric Oncology Department; National Cancer Institute; Cairo University; Giza; Egypt; Clinical Pathology Department; Faculty of Medicine; New Giza University; Giza; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts (MSA); Giza; Egypt
Hepatitis C virus (HCV) infection is a major public health problem, having a high prevalence in Egypt. Leukemia and lymphoma have been associated with HCV infection. MicroRNA-155 (miR-155) has been reported to play a regulatory role in cancer, inflammation, and immune response to infection. The expression level of miR-155 in HCV viremic patients is controversial; although high miR-155 levels were demonstrated in HCV genotypes 1,2, and 3, low levels of miR-155 were detected in Egyptian patients with HCV genotype 4. Several studies have investigated the correlation between the levels of miRNA-155 and the replication of HCV, others have evaluated miRNA-155 as a prognostic biomarker in different types of cancer. No studies have investigated the impact of miRNA-155 knockdown on HCV pediatric patients associated with childhood acute lymphoblastic leukemia (ALL). We knocked-out the miR_155a in cultured polymorphonuclear cells (PBMCs) obtained from 60 children with ALL; 30 were associated with HCV-4 infection and 30 were HCV negative. The miR_155a, HCV viral load, and cell proliferation werre assessed in treated and untreated cells using TaqMan assay quantitative polymerase chain reaction. We found that miRNA-155 was significantly upregulated by seven folds in the HCV-4 associated ALL group; while being linked to high HCV viral load and leukemic burden, miR_155a knock-out can improve the disease outcome. We conclude that miR-155 is a critical miRNA that is considered a therapeutic target in pediatric HCV leukemic patients. 2019 Wiley Periodicals, Inc.
Interaction between 12p chromosomal abnormalities and Lnc-HOTAIR mediated pathway in acute myeloid leukemia
(Wiley-Liss Inc., 2019) El-Khazragy N.; Ghozy S.; Matbouly S.; Zaki W.; Safwat G.; Hussien G.; Khalifa O.; Clinical Pathology and Haematology Department; Faculty of Medicine; Ain Shams University Biomedical Research Department; Cairo; Egypt; Neurosurgery Department; Faculty of Medicine; Mansoura University; Mansoura; Egypt; Department of Paediatric; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Department of Biochemistry; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Department of Molecular Biology; Faculty of Biotechnology; October University for Modern Sciences and Arts (MSA); Cairo; Egypt
Objectives: To investigate the correlation of homeobox (HOX) transcript antisense RNA expression with clinicopathological features and the clinical prognosis of the patients with chromosome 12p abnormalities associated acute myeloid leukemia (AML). We also investigate the association of 12p chromosomal on the expression of HOTAIR, miRNA-193a, and c-kit gene as targeting genes for HOTAIR in AML. Methods: AML patients with 12p chromosomal abnormalities were recruited and compared to AML with other chromosomal abnormalities rather than 12p. The long noncoding RNA (lncRNA) �HOTAIR,� miR-193a, and c-Kit genes expression were measured in bone marrow samples using Syber green based real-time polymerase chain reaction. Results: We found a significant difference for the expression levels of HOTAIR, c-kit, and miR-193a between 12p abnormalities associated AML and those without. The survival analysis revealed that patient's with low expression levels of HOTAIR and c-kit had significantly better survival and leukemia free survival. In contrast, miR-193a was associated with better overall survival but not leukemia free survival. Conclusion: 12p abnormalities associated AML were associated with worse prognosis. Our results proved that HOTAIR, miR-193a, and c-kit genes are independent prognostic predictors in 12p chromosomal associated AML; therefore it may represent a novel therapeutic application in AML in the future. � 2019 Wiley Periodicals, Inc.
The prognostic significance of the long non-coding RNAs “CCAT1, PVT1” in t(8;21) associated Acute Myeloid Leukemia
(Elsevier B.V., 2019) El-Khazragy N.; Elayat W.; Matbouly S.; Seliman S.; Sami A.; Safwat G.; Diab A.; Clinical Pathology and Hematology Department; Faculty of Medicine; Ain Shams University Biomedical Research Department; P.O. Box 11381; Cairo; Egypt; Department of Medical Biochemistry; Faculty of Medicine; Ain Shams University; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts (MSA); Cairo; Egypt
Long non-coding RNA (LncRNA) is recently linked to various types of cancers, CCAT and PVT1 are two LncRNAs linked to t(8;21) associated Acute Myeloid Leukemia, the interplay between CCAT, PVT1 and the MYC proto-oncogene implicated in t(8;21) could present an opportunity for using LncRNA as prognostic biomarker or a target for therapy, We investigated the expression levels of LncRNAs in 70 patients; 30 with t(8;21) positive AML and 40 with t(8;21) negative AML, We found that CCAT1 and PVT1 are expressed in higher levels in t(8;21) positive �AML by 5.3 folds compared to t(8;21) negative group; the expression values were significantly associated with high-risk clinical criteria; moreover, they are associated with lower overall survival (OS) rate and leukemia-free survival (LFS), however we didn't find a statistically significant cut-off value of LncRNAs using the Cox regression analysis for Lnc_PVT1 except with LFS, we conclude that high expression levels of CCAT1 and PVT1 are associated with poor prognosis while being poor prognostic biomarkers in t(8;21) associated AML. � 2019 Elsevier B.V.